Antitumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma

Схожие документы

• Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells
  по: Suzuki, Rikio, et al.
  Опубликовано: (2015)
• Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition
  по: Mimura, Naoya, et al.
  Опубликовано: (2014)
• Histone deacetylase 3 (HDAC3) as a novel therapeutic target in multiple myeloma
  по: Minami, Jiro, et al.
  Опубликовано: (2013)
• Small Molecule Multi-Targeted Kinase Inhibitor RGB-286638 Triggers P53-Dependent and -Independent Anti-Multiple Myeloma Activity through Inhibition of Transcriptional CDKs
  по: Cirstea, Diana, et al.
  Опубликовано: (2013)
• p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma
  по: Hideshima, Teru, et al.
  Опубликовано: (2017)